论文部分内容阅读
目的:观察和探讨肿瘤干细胞标志物CD44v6和CD24在卵巢浆液性癌中的表达特点,并分析其与临床病理参数和预后的关系。方法:选2009年6月-2013年6月就诊的卵巢浆液性癌进行手术切除的76例标本作为研究观察对象,采用两级病理分级系统对组织学分级进行判定,应用免疫组织化学EnVision二步法对癌组织中的CD44v6和CD24的表达进行检测,针对检查结果和对患者随访情况,对其与卵巢浆液性癌发展关系进行分析。结果:CD44v6阳性表达率为44.74%,主要表达于细胞膜;而CD24阳性表达率为63.16%,主要表达于细胞膜,可有腔缘表达;部分表达于细胞质,可有腔缘表达。两者均有表达共25例,比率为32.89%。CD44v6阳性与阴性之间生存率有显著差异(P<0.05);而CD24阳性与阴性之间生存率无显著差异(P>0.05)。CD44v6和CD24不同病理分级中表达有显著性差异(P<0.05),而在年龄、临床分级方面无显著相关性(P>0.05)。76例患者全部得到随访资料,其中随访复发45例,时间为手术后2-72个月之间,平均无瘤生存期为(33.5±12.7)月;共死亡21例,时间为术后6-57个月之间,平均生存时间为(43.6±17.6)月。CD44v6阳性与阴性病例相比较无瘤生存时间、死亡率和生存时间差异均显著(P<0.05);年龄为预后的独立影响因子(P<0.05)。结论:卵巢浆液性癌主要的不良因素为CD44v6和高龄,病理分级系统也与疾病预后有密切的关联。
OBJECTIVE: To observe and explore the expression characteristics of tumor stem cell markers CD44v6 and CD24 in ovarian serous carcinoma and to analyze its relationship with clinicopathological parameters and prognosis. Methods: Totally 76 specimens of surgical resection of ovarian serous carcinoma treated in our hospital from June 2009 to June 2013 were selected as the research object. Tissue grading was evaluated by two-stage pathological grading system. The immunohistochemistry EnVision two-step Act on the expression of CD44v6 and CD24 in cancer tissue were detected for the examination results and follow-up of patients with its relationship with the development of ovarian serous carcinoma were analyzed. Results: The positive expression rate of CD44v6 was 44.74%, which was mainly expressed in the cell membrane. The positive expression rate of CD24 was 63.16%, which was mainly expressed in the cell membrane and could be expressed in the marginal cavity. Both of them have a total expression of 25 cases, the rate was 32.89%. The survival rates of CD44v6 positive and negative were significantly different (P <0.05), but there was no significant difference between CD24v6 positive and negative (P> 0.05). CD44v6 and CD24 expression in different pathological grades were significantly different (P <0.05), but in age, clinical grade no significant correlation (P> 0.05). All 76 patients were followed up, of which 45 cases were followed up for a mean time of 2-72 months after surgery. The mean tumor-free survival was 33.5 ± 12.7 months. Twenty-one patients died of 6- 57 months, the average survival time was (43.6 ± 17.6) months. CD44v6 positive and negative cases of tumor-free survival time, mortality and survival time were significantly different (P <0.05); age as an independent prognostic factor (P <0.05). Conclusion: The main adverse factors of ovarian serous carcinoma are CD44v6 and elderly, and the pathological grading system is also closely related to the prognosis of the disease.